Court order restricts Cable One acquisition and $2.45 billion financing plan
Key Facts
Cable One's purchase of the remaining stake in Mega Broadband faces a temporary restraining order issued on October 9, 2026, while implementation of a refinancing plan targeting $2.45 billion in obligations depends on resolving legal restrictions, according to a company update. Cable One said the proposed refinancing aims to address its existing obligations and near-term debt maturities. Implementation is subject to resolution of the restraining order or any other legal restriction preventing it, under the terms the company outlined in its deal update. At the time of the update, Cable One had not entered into definitive financing agreements for the proposed financing. It said "no definitive financing agreements have yet been entered into."
The pending acquisition targets a 55% stake in Mega Broadband Investments Holdings that Cable One does not already own, according to the acquisition announcement. The company currently holds a 45% stake in Mega Broadband and is seeking full ownership by purchasing the remaining interest. The legal dispute relates to a complaint filed by lender CoBank over payment of the acquisition price, according to Cable One's account in its update. The complaint alleges that the payment would constitute a "constructive fraudulent transfer," the characterization underpinning the lender's objection to the transaction. Cable One disputes the allegation in a case concerning payment for the targeted stake and completion of its transfer to the buyer.
In the IPO market, Iambic Therapeutics announced the pricing of its initial public offering at $16.00 per share and set October 15, 2026, as the date for trading to begin on Nasdaq under the symbol IAM. The base offering comprised 9,375,000 common shares, all offered by the company itself, according to the pricing announcement. Iambic estimated expected gross proceeds of about $150.0 million, before underwriting discounts, commissions and offering expenses. The company granted underwriters an option to purchase additional shares beyond the announced base offering. The option runs for 30 days and allows the purchase of up to 1,406,250 additional shares at the offering price, less underwriting discounts and commissions.
In another pharmaceutical deal, TriGemX Bio expects gross proceeds of about $246 million at the closing of its merger with TCGX, according to an announcement filed with the U.S. Securities and Exchange Commission. The estimate is before transaction costs and assumes no redemptions by TCGX's public shareholders. The deal includes $160 million in concurrent private investment in public equity financing, according to the announced financing terms. The combined company's equity value at closing is estimated at about $600 million, a valuation of the entity resulting from the merger. The equity estimate also assumes no redemptions by public shareholders, according to the announcement.
In mining, Almonty Industries scheduled its investor day for October 19, 2026, starting at 9:00 a.m. U.S. Eastern Time, according to a company announcement. The program includes a presentation on the tungsten market alongside operational updates on the company's mines. Providing operational context for the program, Almonty's president said the Sangdong mine had entered commercial production. He said the company was also proceeding with the second phase of the mine's development, as part of his update on progress at the site. The company's president said in the announcement: "Sangdong is now in commercial production, and phase two is officially moving forward," linking its current operating status to the next development step.
On the upcoming timetable, TriGemX and TCGX expect to complete their merger in the first quarter of 2027, according to the announcement filed with the U.S. regulator. Completion remains subject to shareholder approval of the merger under the terms announced by the companies. Closing also requires satisfaction of other conditions, alongside shareholder approval, before the transaction can be completed on the expected schedule. In clinical development, TriGemX expects to announce results from the first phase three trial of elismetrep in mid-2027. The drug is being developed to treat acute migraine, and the expected trial results are due after the targeted merger completion period, according to the timetable announced by the companies.